Replimune Group, Inc. Forecasted to Post Q1 2026 Earnings of ($0.91) Per Share (NASDAQ:REPL)

Replimune Group, Inc. (NASDAQ:REPL - Free Report) - Wedbush issued their Q1 2026 earnings estimates for shares of Replimune Group in a research report issued on Thursday, May 16th. Wedbush analyst R. Driscoll expects that the company will earn ($0.91) per share for the quarter. The consensus estimate for Replimune Group's current full-year earnings is ($3.28) per share. Wedbush also issued estimates for Replimune Group's Q2 2026 earnings at ($0.76) EPS, Q3 2026 earnings at ($0.78) EPS and Q4 2026 earnings at ($0.61) EPS.

Replimune Group Price Performance

Shares of NASDAQ REPL traded down $0.28 during midday trading on Friday, reaching $6.44. 964,908 shares of the company were exchanged, compared to its average volume of 1,210,660. The stock's 50-day moving average price is $7.28 and its 200-day moving average price is $8.39. The stock has a market cap of $395.35 million, a P/E ratio of -2.04 and a beta of 1.25. The company has a quick ratio of 12.40, a current ratio of 12.40 and a debt-to-equity ratio of 0.16. Replimune Group has a one year low of $5.86 and a one year high of $24.81.

Institutional Investors Weigh In On Replimune Group

Several hedge funds have recently modified their holdings of REPL. Fcpm Iii Services B.V. acquired a new position in Replimune Group in the 4th quarter valued at approximately $41,024,000. Goldman Sachs Group Inc. increased its holdings in Replimune Group by 300.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,238,883 shares of the company's stock valued at $18,874,000 after purchasing an additional 1,679,553 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Replimune Group by 12.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company's stock valued at $53,505,000 after purchasing an additional 699,679 shares during the period. Vontobel Holding Ltd. bought a new position in Replimune Group during the 4th quarter worth $2,575,000. Finally, Rafferty Asset Management LLC lifted its holdings in Replimune Group by 148.1% during the 4th quarter. Rafferty Asset Management LLC now owns 463,397 shares of the company's stock worth $3,906,000 after buying an additional 276,596 shares during the period. Institutional investors and hedge funds own 92.53% of the company's stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.